Opendata, web and dolomites

NANO-GROWTH

An innovative, non-invasive and de-risked system to enable the transdermal delivery of fragile therapeutic compounds for a better management of painful diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NANO-GROWTH project word cloud

Explore the words cloud of the NANO-GROWTH project. It provides you a very rough idea of what is the project "NANO-GROWTH" about.

41    severe    astracime    efficiency    transdermal    pain    quality    painful    layers    position    patch    secures    therapeutic    unbearable    dermal    persists    financial    customized    life    proven    heart    globally    patients    neuropathy    longer    people    receive    commercial    reduce    scarcity    leader    effect    rate    transdermally    release    consolidate    revenues    diseases    patches    cure    becomes    instance    helping    topical    solutions    biodegradation    chronic    healthcare    inflicting    encapsulated    innovative    secure    analgesics    nerve    encloses    nano    capsule    damage    relief    altogether    poor    market    cancer    billion    combined    engineered    travel    administered    medication    millions    mature    suffering    34    stage    disease    integrity    adverse    hire    compounds    million    age    worldwide    mediated    barriers    subsequent    skin    gain    turn    loaded    lab    143    overcomes    safer    meds    perspectives    bloodstream    diabetes    solution    saturated    protects    creams    limitations   

Project "NANO-GROWTH" data sheet

The following table provides information about the project.

Coordinator
ASTRACIME SL 

Organization address
address: CALLE MONTE AUSEVA 10 BAJO
city: OVIEDO
postcode: 33012
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.nanogrowth.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASTRACIME SL ES (OVIEDO) coordinator 50˙000.00

Map

 Project objective

Chronic pain affects 1.5 billion people worldwide, which means that pain affects more people than diabetes, heart disease and cancer combined. Since chronic pain persists for years, it becomes unbearable. Chronic pain is often the result from neuropathy (nerve damage), which increases with age but also due to chronic diseases. For instance, 34% of diabetes cases develop painful neuropathy, which means 143 million people affected globally. Since there is no cure, patients receive analgesics and other meds for pain relief. To avoid inflicting further pain, medication is administered transdermally using topical solutions like creams or patches. However, there are important barriers to the dermal delivery of analgesics: scarcity of viable compounds, high biodegradation rate, short effect, poor efficiency and severe adverse effects. In response, we at Astracime have developed an innovative solution that overcomes the limitations of transdermal pain relief. This NANO-GROWTH project aims to bring to market a unique dermal patch loaded with encapsulated therapeutic compounds. The customized capsule protects the integrity of the compounds as they travel through the skin layers and bloodstream. In addition, we have engineered the capsule to provide target-mediated release. Altogether, our method secures a longer and safer pain relief. After been proven at the lab scale, we now aim to take a step further towards the mature stage. Thus, in Phase 1 we aim to assess the subsequent steps needed to secure this project from all technical, commercial and financial perspectives. This project encloses significant growth potential for Astracime, allowing us to consolidate a leader position in the field of pain management. Indeed, we expect to gain €41 million in revenues and hire 30 new people in 5 years. In turn, this project will contribute to improve the quality of life of millions of patients suffering from pain, while helping to reduce costs to our saturated healthcare system.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANO-GROWTH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NANO-GROWTH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

Vacc-iNTS (2019)

Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa

Read More  

FURTHER (2019)

Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone Metastasis

Read More